Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.

Kikuchi K, Tancharoen S, Ito T, Morimoto-Yamashita Y, Miura N, Kawahara K, Maruyama I, Murai Y, Tanaka E.

Int J Mol Sci. 2013 Sep 13;14(9):18899-924. doi: 10.3390/ijms140918899. Review. Erratum in: Int J Mol Sci. 2014;15(4):5410-1.

2.

The different isoforms of the receptor for advanced glycation end products are modulated by pharmacological agents.

Grossin N, Boulanger E, Wautier MP, Wautier JL.

Clin Hemorheol Microcirc. 2010;45(2-4):143-53. doi: 10.3233/CH-2010-1292. Review.

PMID:
20675894
3.

Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.

Antoniou T, Camacho X, Yao Z, Gomes T, Juurlink DN, Mamdani MM.

CMAJ. 2013 Sep 3;185(12):1035-41. doi: 10.1503/cmaj.121771. Epub 2013 Jul 8.

4.

Effects of candesartan cilexetil and amlodipine orotate on receptor for advanced glycation end products expression in the aortic wall of Otsuka Long-Evans Tokushima Fatty (OETFF) type 2 diabetic rats.

Kang MK, Chung WB, Hong SK, Kim OR, Ihm SH, Chang K, Seung KB.

Arch Pharm Res. 2016 Apr;39(4):565-76. doi: 10.1007/s12272-016-0728-6. Epub 2016 Mar 9.

PMID:
26960737
5.
6.

An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies.

Musumeci D, Roviello GN, Montesarchio D.

Pharmacol Ther. 2014 Mar;141(3):347-57. doi: 10.1016/j.pharmthera.2013.11.001. Epub 2013 Nov 9. Review.

PMID:
24220159
7.
8.

Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury.

Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S.

Pharmacol Res. 2012 Mar;65(3):297-302. doi: 10.1016/j.phrs.2011.11.001. Epub 2011 Nov 10.

PMID:
22100460
9.

Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.

Rizos CV, Milionis HJ, Kostapanos MS, Florentin M, Kostara CE, Elisaf MS, Liberopoulos EN.

Clin Ther. 2010 Mar;32(3):492-505. doi: 10.1016/j.clinthera.2010.03.018.

PMID:
20399986
10.

The HMGB1 receptor RAGE mediates ischemic brain damage.

Muhammad S, Barakat W, Stoyanov S, Murikinati S, Yang H, Tracey KJ, Bendszus M, Rossetti G, Nawroth PP, Bierhaus A, Schwaninger M.

J Neurosci. 2008 Nov 12;28(46):12023-12031. doi: 10.1523/JNEUROSCI.2435-08.2008.

11.

Candesartan cilexetil: an angiotensin II receptor blocker.

Stoukides CA, McVoy HJ, Kaul AF.

Ann Pharmacother. 1999 Dec;33(12):1287-98. Review.

PMID:
10630830
12.

Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.

Lin JW, Chang CH, Caffrey JL, Wu LC, Lai MS.

Hypertension. 2014 May;63(5):968-76. doi: 10.1161/HYPERTENSIONAHA.113.02550. Epub 2014 Feb 10.

13.

Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression.

Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S.

Pharmacol Res. 2010 Jan;61(1):34-9. doi: 10.1016/j.phrs.2009.07.004. Epub 2009 Jul 25.

PMID:
19635564
14.

Differential clinical profile of candesartan compared to other angiotensin receptor blockers.

Cernes R, Mashavi M, Zimlichman R.

Vasc Health Risk Manag. 2011;7:749-59. doi: 10.2147/VHRM.S22591. Epub 2011 Dec 12. Review.

15.

Clinical use of high mobility group box 1 and the receptor for advanced glycation end products in the prognosis and risk stratification of heart failure: a literature review.

Marsh AM, Nguyen AH, Parker TM, Agrawal DK.

Can J Physiol Pharmacol. 2017 Mar;95(3):253-259. doi: 10.1139/cjpp-2016-0299. Epub 2016 Nov 30. Review.

PMID:
28092162
16.

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.

Schupp M, Janke J, Clasen R, Unger T, Kintscher U.

Circulation. 2004 May 4;109(17):2054-7. Epub 2004 Apr 26.

17.

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.

ARB Trialists Collaboration.

J Hypertens. 2011 Apr;29(4):623-35. doi: 10.1097/HJH.0b013e328344a7de. Review.

PMID:
21358417
19.

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.

Israili ZH.

J Hum Hypertens. 2000 Apr;14 Suppl 1:S73-86. Review.

PMID:
10854085

Supplemental Content

Support Center